Bone mineral density rapidly decreases upon withdrawal from intermittent parathyroid hormone (PTH) treatment despite its potent effect of promoting bone formation. To better understand this adverse phenomenon, this study first aimed to investigate the phenotype of PTH withdrawal in both intact and estrogen-deficient rat model by using a well-designed experiment combined with innovative longitudinal imaging techniques and localized cellular activities. Due to observing a continuous anabolic window upon early discontinuation of PTH treatment in estrogen-deficient animals, we propose a potential effective treatment strategy, the short cycles of PTH and antiresorptive treatment regimen, which could extend the anabolic windows by increasing the ...
Objective: Parathyroid hormone intermittent administration has been considered to treat bone mass de...
Summary: Using in vivo microcomputed tomography (micro-CT), we found in parathyroid hormone (PTH)-tr...
To compare the effect of intermittent parathyroid hormone (PTH) treatment with that of estrogen trea...
Bone mineral density rapidly decreases upon withdrawal from intermittent parathyroid hormone (PTH) t...
The use of Parathyroid Hormone (PTH) as bone anabolic is limited due to cost-benefit assessments. Pr...
Basic Multicellular Units (BMUs) conduct bone remodeling, a critical process of tissue turnover whic...
Copyright © 2015 Rafael Pacheco-Costa et al. This is an open access article distributed under the Cr...
One of only a few approved and available anabolic treatments for severe osteoporosis is daily inject...
Parathyroid hormone (PTH) is an anabolic bone drug approved by the US Food and Drug Administration (...
© 2018 Dr. Silvia TrichiloOsteoporosis (OP) is a progressive bone disease characterised by significa...
Osteoporotic patients treated with antiresorptive or anabolic agents experience an increase in bone ...
Parathyroid hormone (PTH) is under intensive investigation for its anabolic actions in bone and ther...
PURPOSE This study was designed to compare fracture healing in normal and ovariectomized rat, and t...
PTH stimulates osteoblastic cells to form new bone and to produce osteoblast-osteoclast coupling fac...
Osteoporosis is a skeletal disease characterized by a decrease in bone mass and deterioration of bon...
Objective: Parathyroid hormone intermittent administration has been considered to treat bone mass de...
Summary: Using in vivo microcomputed tomography (micro-CT), we found in parathyroid hormone (PTH)-tr...
To compare the effect of intermittent parathyroid hormone (PTH) treatment with that of estrogen trea...
Bone mineral density rapidly decreases upon withdrawal from intermittent parathyroid hormone (PTH) t...
The use of Parathyroid Hormone (PTH) as bone anabolic is limited due to cost-benefit assessments. Pr...
Basic Multicellular Units (BMUs) conduct bone remodeling, a critical process of tissue turnover whic...
Copyright © 2015 Rafael Pacheco-Costa et al. This is an open access article distributed under the Cr...
One of only a few approved and available anabolic treatments for severe osteoporosis is daily inject...
Parathyroid hormone (PTH) is an anabolic bone drug approved by the US Food and Drug Administration (...
© 2018 Dr. Silvia TrichiloOsteoporosis (OP) is a progressive bone disease characterised by significa...
Osteoporotic patients treated with antiresorptive or anabolic agents experience an increase in bone ...
Parathyroid hormone (PTH) is under intensive investigation for its anabolic actions in bone and ther...
PURPOSE This study was designed to compare fracture healing in normal and ovariectomized rat, and t...
PTH stimulates osteoblastic cells to form new bone and to produce osteoblast-osteoclast coupling fac...
Osteoporosis is a skeletal disease characterized by a decrease in bone mass and deterioration of bon...
Objective: Parathyroid hormone intermittent administration has been considered to treat bone mass de...
Summary: Using in vivo microcomputed tomography (micro-CT), we found in parathyroid hormone (PTH)-tr...
To compare the effect of intermittent parathyroid hormone (PTH) treatment with that of estrogen trea...